Your browser doesn't support javascript.
loading
Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Hennessy, Marlene; Wahba, Andrew; Felix, Kumar; Cabrera, Mariella; Segura, Maria Gabriela; Kundra, Vikas; Ravoori, Murali K; Stewart, John; Kleinerman, Eugenie S; Jensen, Vanessa Behrana; Gopalakrishnan, Vidya; Pena, Rhoneil; Quach, Phi; Kim, Grace; Kivimäe, Saul; Madakamutil, Loui; Overwijk, Willem W; Zalevsky, Jonathan; Gordon, Nancy.
Afiliação
  • Hennessy M; Nektar Therapeutics, San Francisco, California, USA.
  • Wahba A; Children's Memorial Hermann Hospital, UT Health Science Center, Houston, Texas, USA.
  • Felix K; Department of Pharmaceutical Sciences, Hampton University, Hampton, Virginia, USA.
  • Cabrera M; Department of Pediatrics, Lincoln Medical and Mental Health Center, New York, New York, USA.
  • Segura MG; Children's Memorial Hermann Hospital, UT Health Science Center, Houston, Texas, USA.
  • Kundra V; Division of Pediatrics, Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ravoori MK; Division of Pediatrics, Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Stewart J; Division of Pediatrics, Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kleinerman ES; Division of Pediatrics, Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jensen VB; Division of Pediatrics, Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gopalakrishnan V; Division of Pediatrics, Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pena R; Nektar Therapeutics, San Francisco, California, USA.
  • Quach P; Nektar Therapeutics, San Francisco, California, USA.
  • Kim G; Nektar Therapeutics, San Francisco, California, USA.
  • Kivimäe S; Verge Genomics, South San Francisco, California, USA.
  • Madakamutil L; Nektar Therapeutics, San Francisco, California, USA.
  • Overwijk WW; Nektar Therapeutics, San Francisco, California, USA.
  • Zalevsky J; Invivoscribe, San Diego, CA, USA.
  • Gordon N; Nektar Therapeutics, San Francisco, California, USA.
Int J Cancer ; 148(8): 1928-1937, 2021 04 15.
Article em En | MEDLINE | ID: mdl-33152115
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polietilenoglicóis / Neoplasias Ósseas / Protocolos de Quimioterapia Combinada Antineoplásica / Osteossarcoma / Interleucina-2 / Modelos Animais de Doenças Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polietilenoglicóis / Neoplasias Ósseas / Protocolos de Quimioterapia Combinada Antineoplásica / Osteossarcoma / Interleucina-2 / Modelos Animais de Doenças Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos